The immunology and prevention of isocyanate asthma: A model for low molecular weight asthma

Seminars in Respiratory and Critical Care Medicine

Volumn 20, Issue 6, 1999, Pages 591-599

  Redlich, Carrie A ^a   Cain, Hilary ^a   Wisnewski, Adam V ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Isocyanate asthma; Isocyanates; Occupational asthma

Indexed keywords

IMMUNOGLOBULIN E; ISOCYANATE;

HUMAN; HUMAN TISSUE; IMMUNOPATHOLOGY; INFLAMMATION; ISOCYANATE ASTHMA; OCCUPATIONAL ALLERGY; OCCUPATIONAL ASTHMA; OCCUPATIONAL HAZARD; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; T LYMPHOCYTE;

EID: 0033397989     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1009478     Document Type: Review

References (49)

1. Chan-Yeung M, Malo JL. Occupational asthma. N Engl J Med 1995;333:107-112
2. Chan-Yeung M, Malo JL. Aetological agents in occupational asthma. Eur Respir J 1994;7:346-371
3. Cullinan P. Occupational asthma, IgE and IgG. Clin Exp Allergy 1998;28:668-670 Editorial
4. Venables KM, Chan-Yeung M. Occupational asthma. Lancet 1997;349:1465-1469
5. Raulf-Heimsoth M, Baur X. Pathomechanisms and pathophysiology of isocyanate-induced diseases - summary of present knowledge. Am J Ind Med 1998;34:137-143
6. Baur X. Occupational asthma due to isocyanates. Lung 1996;174:23-30
7. Bernstein JA. Overview of diisocyanate occupational asthma. Toxicology 1996;111:181-189
8. Maestrelli P, Saetta M, Mapp C, Fabrri LM. Mechanisms of occupational asthma. Clin Exp Allergy 1997;27:47-54
9. 14C-labeled methyl isocyanate. Fundam Appl Toxicol 1993;20:57-67
10. Jin R, Day BW, Karol MH. Toluene diisocyanate protein adducts in the bronchoalveolar lavage of guinea pigs exposed to vapors of the chemical. Chem Res Toxicol 1993;6:906-912
11. Sepai O, Schutze D, Heinrich U, Hoymann HG, Henschler D, Sabbioni G. Hemoglobin adducts and urine metabolites of 4,4′-methylenedianiline after 4,4′-methylenediphenyl diisocyanate exposure of rats. Chem Biol Interact 1995;97: 185-198
12. Wisnewski AV, Lemus R, Karol MH, Redlich CA. Isocyanate-conjugated lung epithelial cell proteins: A link between exposure and asthma? J Allergy Clin Immunol, 1999;104: 341-347
13. Redlich CA, Karol MH, Graham C, et al. Demonstration of airway isocyanate-adducts in human HDI-induced asthma. Scand J Work Environ Health 1997;23:227-231
14. Sepai O, Henschler D, Sabbioni G. Albumin adducts, hemoglobin adducts and urinary metabolites in workers exposed to 4,4′-methylenediphenyl diisocyanate. Carcinogenesis 1995;16:2583-2587
15. Lind P, Dalene M, Skarping G, Hagmar L. Toxicokinetics of 2,4-and 2,6-toluenediamine in hydrolyzed urine and plasma after occupational exposure to 2,4-and 2,6-toluene diisocyanate. Occup Environ Med 1996;53:94-99
16. Schutze D, Sepai O, Lewalter J, Miksche L, Henschler D, Sabbioni G. Biomonitoring of workers exposed to 4,4′-methylenedianiline or 4,4′-methylenediphenyl diisocyanate. Carcinogenesis 1995;16:573-582
17. National Institute for Occupational Safety and Health. Preventing Asthma and Death from Diisocyanate Exposure. 1996. Public Health Service, Center for Disease Control Alert 96-111
18. Kimber I. The role of the skin in the development of chemical respiratory hypersensitivity. Toxicol Lett 1996;86:89-92
19. Vandenplas O, Cartier A, Lesage J, et al. Prepolymers of hexamethylene diisocyanate as a cause of occupational asthma. J Allergy Clin Immunol 1993;91:850-861
20. Vandenplas O, Malo JL, Saetta M, Mapp CE, Fabbri LM. Occupational asthma and extrinsic allergic alveolitis due to isocyanates: Current status and perspectives. Br J Ind Med 1993;50:213-218
21. Rattray NJ, Botham PA, Hext PM, et al. Induction of respiratory hypersensitivity to diphenylmethane 4,4′-diisocyanate (MDI) in guinea pigs. Influence of the route of exposure. Toxicology 1994;88:15-30
22. Tee RD, Cullinan P, Welch J, Burge PS, Newman-Taylor AJ. Spiecific IgE to isocyanates: A useful diagnostic role in occupational asthma. J Allergy Clin Immunol 1998;101:709-715
23. Son M, Lee M, Kim YT, Youn JK, Park H. Heterogeneity of IgE response to TDI-HSA conjugates by ELISA in toluene diisocyanate (TDI)-induced occupational asthma (OA) patients. J Korean Med Sci 1998;13:147-152
24. Karol MH, Tollerud DJ, Campbell TP, et al. Predictive value of airways hyperresponsiveness and circulating IgE for identifying types of responses to toluene diisocyanate inhalation challenge. Am J Respir Crit Care Med 1994;149: 611-615
25. Yokota K, Yamaguchi K, Takeshita T, Morimoto K. The significance of specific IgG4 antibodies to methyltetrahydrophthalic anhydride in occupationally exposed subjects. Clin Exp Allergy 1998;28:694-701
26. Grammer LC, Harris KE, Malo JL, Cartier A, Patterson R. The use of an immunoassay index for antibodies against isocyanate human protein conjugates and application to human isocyanate disease. J Allergy Clin Immunol 1990;86: 94-98
27. Bentley AM, Maestrelli P, Saetta M, et al. Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma. J Allergy Clin Immunol 1992;89: 821-829
28. Frew A, Chang JH, Chan H, et al. T-lymphocyte responses to plicatic acid-human serum albumin conjugate in occupational asthma caused by western red cedar. J Allergy Clin Immunol 1998;101:841-847
29. Saetta M, Maestrelli P, DiStefano A, et al. Effect of cessation of toluene diisocyanate (TDI) on bronchial mucosa of subjects with TDI-induced asthma. Am Rev Respir Dis 1992; 145:169-174
30. Maestrelli P, Occari P, Turato G, et al. Expression of interleukin (IL)-4 and IL-5 proteins in asthma induced by toluene diisocyanate (TDI). Clin Exp Allergy 1997;27:1292-1298
31. Frew AJ, Chan H, Lam S, Chan-Yeung M. Bronchial inflammation in occupational asthma due to western red cedar. Am J Respir Crit Care Med 1995;151:340-344
32. Maestrelli P, Del Prete GF, De Carli M, et al. CD8 T-cell clones producing interleukin-5 and interferon-gamma in bronchial mucosa of patients with asthma induced by toluene diisocyanate. Scand J Work Environ Health 1994;20:376-381
33. Finotto S, Fabbri LM, Rado V, Mapp CE, Maestrelli P. Increase in numbers of CD8 positive lymphocytes and eosinophils in peripheral blood of subjects with late asthmatic reactions induced by toluene diisocyanate. Br J Ind Med 1991;48:116-121
34. Avery SB, Stetson DM, Pan PM, Mathews KP. Immunological investigation of individuals with toluene diisocyanate asthma. Clin Exp Immunol 1969;4:585-596
35. Bernstein JA, Munson J, Lummus Z, et al. TCR V-segment expression in isocyanate asthma. J Allergy Clin Immunol 1998;102:265-274
36. Lummus ZL, Alam R, Bernstein JA, Bernstein DI. Diisocyanate antigen-enhanced production of monocyte chemoattractant protein-1, IL-8, and tumor necrosis factor-alpha by peripheral mononuclear cells of workers with occupational asthma. J Allergy Clin Immunol 1998;102:265-274
37. Wisnewski AV, Karol MH, Lemus R, et al. Lymphocyte responses in isocyanate asthma. Am J Respir Crit Care Med 1999;159:A234
38. Bignon JS, Aron Y, Ju LY, et al. HLA class II alleles in isocyanate-induced asthma. Am J Respir Crit Care Med 1994;149:71-75
39. Rihs HP, Barbalho-Krolls T, Huber H, Baur X. No evidence for the influence of HLA class II in alleles in isocyanate-induced asthma. Am J Ind Med 1997;32:522-527
40. Perrin B, Cartier A, Ghezzo H, et al. Reassessment of the temporal patterns of bronchial obstruction after exposure to occupational sensitizing agents. J Allergy Clin Immunol 1991;87:630-639
41. Perfetti L, Cartier A, Ghezzo H, Gautrin D, Malo JL. Follow-up of occupational asthma after removal from or diminution of exposure to the responsible agent: Relevance of the length of the interval from cessation of exposure. Chest 1998;114:398-403
42. Lemiere C, Cartier A, Dolovich J, et al. Outcome of specific bronchial responsiveness to occupational agents after removal from exposure. Am J Respir Crit Care Med 1996;154:329-333
43. Malo JL, Ghezzo H, L'Archeveque J, et al. Is the clinical history a satisfactory means of diagnosing occupational asthma? Am Rev Respir Dis 1991;143:528-532
44. Tarlo SM, Boulet LP, Cartier A, et al. Canadian Thoracic Society guidelines for occupational asthma. Can Respir J 1998;5:289-300
45. Perrin B, Lagier F, L'Archeveque J, et al. Occupational asthma: Validity of monitoring of peak expiratory flow rates and non-allergic bronchial responsiveness as compared to specific inhalation challenge. Eur Respir J 1992;5:40-48
46. Chan-Yeung M. Assessment of asthma in the workplace. ACCP consensus statement. American College of Chest Physicians. Chest 1995;108:1084-1117
47. Paggiaro PL, Vagaggini B, Bacci E, et al. Prognosis of occupational asthma. Eur Respir J 1994;7:761-767
48. Perfetti L, Cartier A, Ghezzo H, Gautrin D, Malo JL. Follow-up of occupational asthma after removal from or diminution of exposure to the responsible agent. Relevance of the length of the interval from cessation of exposure. Chest 1998;114:398-403
49. Tarlo SM, Banks D, Liss G, Broder I. Outcome determinants for isocyanate induced occupational asthma among compensation claimants. Occup Environ Med 1997;54:756-761